Which drugs cannot be used with regorafenib (Belvango) and the potential risks

Regorafenib (trade name Stivarga) is an oral multi-target tyrosine kinase inhibitor used to treat metastatic colorectal cancer, gastrointestinal stromal tumor (GIST) and hepatocellular carcinoma. It can inhibit tumor cell proliferation, angiogenesis and signaling pathways in the tumor microenvironment, thereby delaying disease progression. However, due to its complex metabolic pathways, regorafenib needs to pay attention to its interactions with other drugs in clinical application to avoid increasing adverse reactions or reducing efficacy.

Regofenib is mainly metabolized by liverCYP3A4 enzyme and is also a UGT1A9 substrate. Therefore, the following drugs should not be used at the same time or should be used with caution:

1.PowerfulCYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, etc.) may increase the plasma concentration of regorafenib and increase the risk of toxicity.

2.PowerfulCYP3A4 inducers (such as rifampicin, carbamazepine, St. John's wort) may reduce the plasma concentration of regorafenib and reduce the efficacy.

In addition toCYP3A4 related drugs, regorafenib may also interact adversely with the following drugs:

1. Anticoagulant drugs (such as warfarin): Regorafenib may increase the risk of bleeding, and coagulation function needs to be closely monitored.

2.Heart drugs (such as amiodarone, quinidine): may increase the risk of QT interval prolongation, and regular monitoring of electrocardiogram is required.

3.Highly protein-bound drugs: Regorafenib can compete with other highly protein-bound drugs, affecting drug distribution and efficacy.

In clinical applications, doctors should comprehensively evaluate the patient's medication history and avoid concurrent use with strongCYP3A4 inhibitors or inducers. If combined use is necessary, the dosage should be adjusted and drug blood concentrations and adverse reactions should be closely monitored. Patients should avoid adding Chinese herbal medicine or health products on their own while taking the medicine, and regularly review liver and kidney function, blood pressure and electrocardiogram to minimize potential risks and ensure the safe and effective use of regorafenib.

Reference link:https://www.drugs.com